Log in to save to my catalogue

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2812507298

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

About this item

Full title

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2023-05, Vol.388 (19), p.1755-1766

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.
We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving children 1 to 3 years of age with...

Alternative Titles

Full title

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2812507298

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2812507298

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2212895

How to access this item